There is a record number of clinical trials driven by rapid growth in regenerative medicine – a space that will continue to grow and outpace the pharmaceutical industry.
One of the most exciting areas in healthcare today is regenerative medicine. This simple term encompasses a rapidly expanding revolution in medical research, which in its application by physicians is allowing the body to heal itself in ways never before seen.
Janet Lambert joined the Alliance for Regenerative Medicine (ARM) as CEO just over a year ago. And what a year it’s been. Recently, I had the opportunity to talk to Lambert about her first year as CEO, what ARM is doing in cell and gene therapies from clinical and commercialization points of view, as well as its areas of short-term focus. Here’s what she had to say.
The Alliance for Regenerative Medicine’s Foundation for Cell and Gene Medicine, an organization that focuses on issues that face regenerative and advanced therapies, recently released a report, prepared by IQVIA, that finds that outcomes-based contracts for products like tisagenlecleucel (Kymriah) and voretigene neparvovec-rzyl (Luxturna) have helped to overcome payers’ skepticism about high-cost drugs.
So far, regenerative medicine and other advanced therapies — including CAR-T and stem cell therapies — haven’t met market expectations because of difficulties determining their value, according to a recent analysis from the ARM Foundation for Cell and Gene Medicine. Innovative payment models have helped overcome payer uncertainty about high upfront costs, according to the foundation’s analysis.
You probably already knew that there’s a ton of activity and investment in the cell and gene therapy space. But just how much? A new report takes a stab at quantifying the excitement.
The Alliance for Regenerative Medicine’s (ARM) report highlights major trends and metrics from the 2018 second quarter in the regenerative medicines sector.
